Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eciskafusp alfa + atezolizumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Eciskafusp alfa + atezolizumab is a combination investigational therapy evaluated in clinical trials for the treatment of advanced cancers. Eciskafusp alfa (RO7284755) is a recombinant fusion protein designed to activate immune responses against tumors, whereas atezolizumab is a humanized anti-PD-L1 monoclonal antibody approved for multiple cancers. Atezolizumab blocks the interaction between PD-L1 and its receptors (PD-1 and CD80) on T cells, thereby restoring T-cell mediated tumor cell killing. The combination is hypothesized to result in synergistic antitumor immunomodulation by both activating effector T cells (eciskafusp alfa) and relieving immune inhibition (atezolizumab)[1][2][5][6].
- Brand names
- Tecentriq (for atezolizumab)
- Other names
- eciskafusp alfaatezolizumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)PDCD1 (Programmed cell death protein 1 receptor)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on eciskafusp alfa + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eciskafusp alfa + atezolizumab.